Navigation Links
Tanespimycin in Medical News

Kosan Opens TIME-1 Pivotal Phase 3 Trial in Multiple Myeloma

...rporated (Nasdaq: KOSN ) today announced that the tanespimycin in Myeloma Evaluation or TIME-1 pivotal Phase 3 trial for tanespimycin as a potential treatment for multiple myeloma is o...lment. TIME-1 is a pivotal Phase 3 trial comparing tanespimycin in combination with bortezomib (Velcade(R)) with b...
Tanespimycin in Medical Technology

Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma

Tanespimycin is the First Hsp90 Inhibitor to Enter Registration Trials HAYWARD, Calif., Sept. 6 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN ) today announced that it has successfully reached a binding agreement with the U.S. Food and Drug Administration (FDA) on th...

Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO

HAYWARD, Calif., June 04, 2007 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated presented preliminary data from a Phase 2 monotherapy trial showing that tanespimycin demonstrated antitumor activity and tolerability in patients with metastatic melanoma, including one patient with a BRAF mut...

Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial

...ster titled, "Phase 2 trial of the Hsp90 inhibitor tanespimycin (Tan) + trastuzumab (T) in patients (pts) with HER...L. "The response data from this Phase 2 trial of tanespimycin plus trastuzumab have grown stronger as more patie...ve been treated, underscoring our observation that tanespimycin is a highly active and tolerable agent in patients...

Kosan Announces Data Presentations at ASCO 2008 Annual Meeting

...on targeting multiple pathways involved in cancer cell growth and survival. tanespimycin (KOS-953) is being tested in combination with Velcade(R) (bortezomib) in patients with multiple myeloma in a clinical program called TIME. tanespimycin is also being studied in HER2-positive metastatic breast cancer in combinat...

Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR

...on targeting multiple pathways involved in cancer cell growth and survival. tanespimycin (KOS-953) is being tested in combination with Velcade(R) (bortezomib) in patients with multiple myeloma in a clinical program called TIME. tanespimycin is also being studied in HER2-positive metastatic breast cancer in combinat...

Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer

...on targeting multiple pathways involved in cancer cell growth and survival. tanespimycin (KOS-953) is being tested in combination with Velcade(R) (bortezomib) in patients with multiple myeloma in a clinical program called TIME. tanespimycin is also being studied in HER2-positive metastatic breast cancer in combinat...

Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash

...alating Phase 1b clinical trial of Hsp90 inhibitor tanespimycin (KOS-953) in combination with bortezomib (Velcade(...n terms of convenience and ease of administration. tanespimycin is clearly an active and manageable agent and is d...ngful antitumor activity and tolerability with the tanespimycin plus bortezomib combination in multiple myeloma ac...

Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial

...rvival. Tanespimycin (KOS-953) is being tested in combination with bortezomib in patients with multiple myeloma in a registration program called TIME. tanespimycin is also being studied in HER2-positive metastatic breast cancer in combination with Herceptin, and as monotherapy in metastatic melanoma. Intravenous ...

Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma

... tanespimycin is Industry's First Hsp90 Inhibitor to Enter Regis...IME Registration Program Utilizes New, Proprietary tanespimycin Formulation HAYWARD...olling patients. This marks the opening of Kosan's tanespimycin in Myeloma Evaluation or "TIME" registration progr...

Kosan Announces Data Presentations at Upcoming AACR Annual Meeting

... safety profile and Molecular of tanespimycin Therapeutics 13 (KOS-5: 953) -- ...lved in cancer cell growth and survival. Kosan's proprietary formulation of tanespimycin (KOS-953) is currently in Phase 1 and 2 clinical trials, primarily for mult...
Tanespimycin in Biological Technology

Kosan Appoints Pamela S. Cohen, M.D., as Chief Medical Officer

...on targeting multiple pathways involved in cancer cell growth and survival. tanespimycin (KOS-953) is being tested in combination with Velcade(R) (bortezomib) in patients with multiple myeloma in a clinical program called TIME. tanespimycin is also being studied in HER2-positive metastatic breast cancer in combinat...

Kosan Biosciences to Present at the Leerink Swann Solid Tumors Roundtable Conference

...on targeting multiple pathways involved in cancer cell growth and survival. tanespimycin (KOS-953) is being tested in combination with Velcade(R) (bortezomib) in patients with multiple myeloma in a clinical program called TIME. tanespimycin is also being studied in HER2-positive metastatic breast cancer in combinat...

Kosan Announces May 1, 2008 Conference Call and Webcast of First Quarter 2008 Financial Results

...on targeting multiple pathways involved in cancer cell growth and survival. tanespimycin (KOS-953) is being tested in combination with Velcade(R) (bortezomib) in patients with multiple myeloma in a clinical program called TIME. tanespimycin is also being studied in HER2-positive metastatic breast cancer in combinat...

Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR

...on targeting multiple pathways involved in cancer cell growth and survival. tanespimycin (KOS-953) is being tested in combination with Velcade(R) (bortezomib) in patients with multiple myeloma in a clinical program called TIME. tanespimycin is also being studied in HER2-positive metastatic breast cancer in combinat...

Kosan Restructures Workforce to Focus Resources on Lead Clinical Programs

...porting advancement of its lead clinical programs, tanespimycin in multiple myeloma and in metastatic breast cance...hways involved in cancer cell growth and survival. tanespimycin (KOS-953) is being tested in combination with Velc...ultiple myeloma in a clinical program called TIME. tanespimycin is also being studied in HER2-positive metastatic ...

Kosan's Board of Directors Appoints Helen S. Kim as Chief Executive Officer

...on targeting multiple pathways involved in cancer cell growth and survival. tanespimycin (KOS-953) is being tested in combination with Velcade(R) (bortezomib) in patients with multiple myeloma in a clinical program called TIME. tanespimycin is also being studied in HER2-positive metastatic breast cancer in combinat...

Kosan Biosciences to Present at the Cowen and Company 28th Annual Health Care Conference

...on targeting multiple pathways involved in cancer cell growth and survival. tanespimycin (KOS-953) is being tested in combination with bortezomib (Velcade(R)) in patients with multiple myeloma in a clinical program called TIME. tanespimycin is also being studied in HER2-positive metastatic breast cancer in combinat...

Kosan Biosciences to Present at the Susquehanna Second Annual SIGnificant Options in Healthcare Conference

...on targeting multiple pathways involved in cancer cell growth and survival. tanespimycin (KOS-953) is being tested in combination with bortezomib (Velcade(R)) in patients with multiple myeloma in a clinical program called TIME. tanespimycin is also being studied in HER2-positive metastatic breast cancer in combinat...

Kosan Announces Senior Management Changes and Clinical Portfolio Priorities

...alue for the company in the near-term. -- The tanespimycin TIME registration program in multiple myeloma, ...myeloma in early 2009. -- Kosan plans to advance tanespimycin in metastatic breast cancer. To lay the groun...Kosan plans to commence enabling studies with tanespimycin as monotherapy and as combination therapy beg...

Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook

... top priorities in 2008 are the advancement of the tanespimycin TIME program in multiple myeloma and the tanespimycin metastatic breast cancer clinical program, and the...hways involved in cancer cell growth and survival. tanespimycin (KOS-953) is being tested in combination with bort...
Other Tags
(Date:12/21/2014)... HealthDay Reporter FRIDAY, Dec. 19, ... addictive than traditional cigarettes, new research finds. Even ... cigarettes, thousands of ex-smokers said they have fewer cravings and ... need to smoke, researchers reported. "The pattern ... e-cig use than for tobacco use," said lead researcher Jonathan ...
(Date:12/21/2014)... Parker & Sons, Inc. a market leader in ... similar home contractor services announces a record number of ... contracting services. The company is considered by many to ... for well over 40 years. Parker and Sons takes ... customer service to the residents and business owners of ...
(Date:12/21/2014)... 21, 2014 CannabisClassifieds.com celebrates marijuana’s new legal ... only one of its kind, the site has provided its ... for 14 years running. It uniquely combines the benefits ... cannabis readily available to the masses. Assuring the potent ... golden ring of public approval. , Shane Chattin, ...
(Date:12/20/2014)... MissyDress, a distinguished special dress supplier, has just ... has drastically cut prices to all its prom dresses ... 30, 2015. Many of the hottest styles are sold ... dresses, and more. , A spokesman for MissyDress says, ... A-line princess prom dresses or sweetheart chiffon prom dresses, ...
(Date:12/20/2014)... The print component of Healthy Aging is distributed ... 160,000 copies and an estimated readership of 420,000. The ... media strategy and across a network of top news ... of the campaign, click here . , The ... of CTV’s The Social. Lainey Lui, Melissa Grelo, ...
Breaking Medicine News(10 mins):Health News:E-Cigarettes Less Addictive Than Regular Cigarettes, Study Finds 2Health News:E-Cigarettes Less Addictive Than Regular Cigarettes, Study Finds 3Health News:Parker & Sons Announces Record Number Of Favorable Reviews In 2014 With Regard To Its Expert Contracting Services 2Health News:Parker & Sons Announces Record Number Of Favorable Reviews In 2014 With Regard To Its Expert Contracting Services 3Health News:CannabisClassifieds.com Maintains its “Craigslist for Cannabis” Standing with Website Re-launch 2Health News:MissyDress: The Prices of Prom Dresses Just Reduced 2Health News:The ladies of The Social urge Canadian women to put themselves first over the holiday season and into the new year in Mediaplanet’s “Women’s Health” campaign 2
(Date:11/18/2014)... Nov. 18, 2014   EyeLock Inc. , ... and MorphoTrust USA (Safran), a leading ... announced a strategic partnership to offer comprehensive biometric ... administration (MVA), airport screening and financial services markets. ... MorphoTrust serves consumers through a nationwide network of ...
(Date:11/12/2014)... Fla. , Nov. 12, 2014 Crossmatch™, ... today that its U.are.U ® fingerprint readers have ... chain in Central Mexico . The ... 2014 to eliminate payroll issues caused by employees clocking ... installing the U.are.U fingerprint readers, Montparnasse relied on paper ...
(Date:11/10/2014)... appearing on U.S. store shelves in early 2010, and ... The small packets can be tossed into a washing ... or powder. The convenience, though, has come with risks ... at Nationwide Children,s Hospital found that from 2012 through ... children younger than 6 years of age swallowing, inhaling, ...
Breaking Biology News(10 mins):EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2Study finds laundry detergent pods, serious poisoning risk for children 2
Other Contents